Emerging drugs in assisted reproduction

Expert Opinion on Emerging Drugs

Volumn 10, Issue 2, 2005, Pages 425-440

  Papanikolaou, Evangelos G ^a   Kolibianakis, Efstratios ^a   Devroey, Paul ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Assisted reproductive technology; GnRH antagonist; In vitro fertilisation; Infertility; Luteinising hormone

Indexed keywords

ANTIESTROGEN; BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL VALERATE; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GOSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; METRODIN HP FSH; NAFARELIN ACETATE; NASANYL; NOVAREL; PROGESTERONE; PUREGON PEN; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; SAMYNAREL; TRIPTORELIN; UNCLASSIFIED DRUG; UROFOLLITROPIN; VASCULOTROPIN;

ABDOMINAL PAIN; ABSCESS; ALLERGIC REACTION; ASSISTED REPRODUCTIVE TECHNOLOGY; BLOATING; BREAST DISEASE; CLINICAL TRIAL; EMBRYO TRANSFER; ENDOMETRIUM; FERTILIZATION IN VITRO; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HYPERSENSITIVITY REACTION; INFERTILITY; INFERTILITY THERAPY; INJECTION PAIN; INTRACYTOPLASMIC SPERM INJECTION; MULTIPLE PREGNANCY; MUSCLE WEAKNESS; NAUSEA; NIDATION; OOCYTE MATURATION; OVARY HYPERSTIMULATION; REVIEW; VOMITING;

CLINICAL TRIALS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; FEMALE; FERTILITY AGENTS; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 18844452914     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.2.425     Document Type: Review

References (84)

1. SPEROFF L, GLASS RH, KASE NG: Infertility. In: Clinical Gynecologic Endocrinology and Infertility (6th Ed). Lippincott Williams & Wilkins, Baltimore, USA (1999):201-246.
2. HEALY DL, TROUNSON AO, ANDERSEN AN: Female infertility: causes and treatment. Lancet (1994) 343:1539-1544.
3. ABMA JC, CHANDRA A, MOSHER WD, PETERSON LS, PICCININO LJ: Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 23. (1997) 19:1-114.
4. LUNENFELD B, MENZI A, VOLET B: Clinical effects of human postmenopausal gonadotropins. Acta Endocrinol. (1960) (Suppl.)51:587.
5. SMITZ J, DEVROEY P, BRAECKMANS P et al.: Management if failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and hMG. Hum. Reprod. (1987) 2:309-314.
6. DEVROEY P, VAN STEIRTEGHEM A, MANNAERTS B, BENNINK HC: Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH. Lancet (1992) 339:I170.
7. ALBANO C, FELBERBAUM RE, SMITZ J et al.: Ovarian stimulation with HMG: results of a prospective randomized Phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. The European Cetrorelix Study Group. Hum. Reprod. (2000) 15:526-531.
8. BORN G, MANNAERTS B: Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum. Reprod. (2000) 15:1490-1498.
9. THE EUROPEAN RECOMBINANT LH STUDY GROUP HUMAN: Recombinant luteinizing hormone is as effective as; but safer than, urinary human chorionic gonadotropin in inducing final maturation and ovulation in vitro fertilization procedures: results of a multicenter double-blind study. J. Clin. Endocrinol. Metab. (2001) 86:2607-2618. A compehensive randomised study comparing recLH and uHCG for inducing final oocyte maturation.
10. STEPTOE PC, EDWARDS RG: Birth after the reimplantation of a human embryo. Lancet (1978) 2:366.
11. LOPATA A, JOHNSTON IW, HOULT IJ, SPEIRS AI: Pregnancy following intrauterine implantation of an embryo obtained by in vitro fertilization of a preovulatory egg. Fertil. Steril. (1980) 33:117-120.
12. PALERMO G, JORIS H, DEVROEY P, VAN STEIRTEGHEM AC: Pregnancies after intracytoplasmic injection of single spermarozoon into an oocyte. Lancet (1992) 340:17-18.
13. ADAMSON D, LANCASTER P, DE MOUZON J, NYGREN KG, ZEGERS-HOCHSHIELD F: INTERNATIONAL WORKING GROUP for REGISTERS on ASSISTED REPRODUCTION (IFFS TASK FORCE): World collaborative report on assisted reproductive technology, 1998. In: Reproductive medicine in the twenty-first century. Healy DL, Kovacs GT, McLachlan R, Rodrigues-Armas O (Eds). Proceedings of the 17th World Congress on Fertility and Sterility, Melbourne Australia. Parthenon, New York, USA (2002):209-219.
14. LLOYD A, KENNEDY R, HUTCHINSON J, SAWYER W: Economic evaluation of higly purified menotropin compared with recombinant follicle stimulating hormone in assisted reproduction. Fertil. Steril. (2003) 80:1108-1113.
15. PAPANIKOLAOU EG, TOURNAYE H, VERPOEST W et al.: Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum. Reprod. (2005) 20:636-641.
16. URBANCSEK J, RABE T, STROWITZKI T: Ovarian stimulation for in vitro fertilization: past and present. In: Manual on Assisted Reproduction, Rabe T, Diedrich K; Strowitzki T (Eds). Springer-Verlag Heidelberg, Germany (2000):165-195.
17. NYGREN KG, ANDERSEN AN: Assisted reproductive technology in Europe, 1999. Results generared from European registers by ESHRE. Hum. Reprod. (2002) 17:3260-3274.
18. DEVROEY P, BOURGAIN C, MACKLON NS, FAUSER BC: Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol. Metab. (2004) 15:84-90.
19. FAUSER BC, DEVROEY P: Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. (2003) 14:236-242. A review of the consequences of ovarian stimulation on the luteal phase and endometrial receptivity.
20. LOPATA A, BROWN JB, LEETON JF, TALBOT JM, WOOD C: In vitro fertilization of preovulatory oocytes and embryo transfer in infertile patients treated with clomiphene and human chorionic gonadotropin. Fertil. Steril. (1978) 30:27-35.
21. MESSINIS IE: Drugs used in in vitro fertilisation procedures. Drugs (1989) 38:148-59. This paper introduces the first steps of IVF.
22. LUNENFELD B, LUNENFELD E, INSLER V: Human Gonadotropins. In: Manual on Assisted Reproduction. Rabe T, Diedrich K, Strowitzki T (Eds). Springer-Verlag Heidelberg, Germany (2000):79-132.
23. LUNENFELD B, SULIMOVICI S, RABAU E, ESHKOL A: L'induction de l'ovulation dans les amenorrhees hypophysates par un traitement combiné de gonadotropines urinaires ménopausiques et de gonadotropines chorioniques. Soc. Fr. Gynecol. (1962) 5:346-351.
24. DICKEY RP, THORNTON M, NICHOLS J, MARSHALL DC, FEIN SH, NARDI RV; BRAVELLE IVF STUDY GROUP: Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta for in vitro fertilization: a prospective, randomized study. Fertil. Steril. (2002) 77:1202-1208.
25. CHUONG CJ, YOUNG RL, BOESCH CL, LEWALLEN NB, REILLY M: Successful pregnancy after treatment with recombinant human follicle stimulating hormone. Lancet (1993) 341:8852.
26. GOLDFARB JM, DESAI N: Follitropin-α versus human menopausal gonadotropin in an in vitro fertilisation program. Fertil. Steril. (2003) 80:1094-1099.
27. OUT HJ, DRIESSEN SG, MANNAERTS BM, COELINGH BENNINK HJ: Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in-vitro fertilization than urinary gonadotropins. Fertil. Steril. (1998) 69(Suppl. 1):S40-S44. A randomised controlled study comparing the effects of rFSH with urinary gonadotrophins with respect to pregnancy rates.
28. DAYA S: Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil. Steril. (2002) 77:711-714.
29. VAN WELY M, WESTERGAARD LG, BOSSUYT PM, VAN DER VEEN F: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst. Rev. (2003) 1:CD003973.
30. AL-INANY H, ABOULGHAR M, MANSOUR R, SEROUR G: Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum. Reprod. (2003) 18:305-313.
31. THE EUROPEAN RECOMBINANT HUMAN LH STUDY GROUP: Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J. Clin. Endocrionol. Metab. (1998) 83:1507-1514.
32. FERRARETTI AP, GIANAROLI L, MAGLI MC, D'ANGELO A, FARFALLI V, MONTANARO N: Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil. Steril. (2004) 8:1521-1526.
33. DE PLACIDO G, ALVIGGI C, PERINO A et al.: Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum. Reprod. (2005) 20(2):390-396.
34. KOLIBIANAKIS EM, ZIKOPOULOS K, SCHIETTECATTE J et al.: Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum. Reprod. (2004) 19:2490-2496.
35. SMITZ J, RON-EL R, TARLATZIS BC: The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres. Hum. Reprod. (1992) 7(Suppl. 1):49-66.
36. TARLATZIS B, BILI H: Safety of GnRH agonists and antagonists. Expert Opin. Drug Saf. (2004) 3:39-46. Reviews safety issues with regards to the use of GnRH analogues in ART.
37. HUIRNE JA, LAMBALK CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet (2001) 358:1793-1803.
38. SHAPIRO DB: An overview of GnRH antagonists in infertility treatments. Introduction. Fertil. Steril. (2003) 80(Suppl. 1):S1-S7.
39. AL-INANY H, ABOULGHAR M: GnRH antagonist in assisted reproduction: a Cochrane review. Hum. Reprod. (2002) 17:874-885.
40. KOLIBIANAKIS EM, ZIKOPOULOS K, SMITZ J et al.: Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum. Reprod. (2004) 7:1525-1529.
41. LUDWIG M, DOODY KJ, DOODY KM: Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil. Steril. (2003) 79:1051-1059.
42. ABDALLA IH, AH-MOYE M, BRISDEN P, HOWE DL, OKONOFUS F, CRAFT I: The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil. Steril. (1987) 48:958-963.
43. THE EUROPEAN RECOMBINANT HUMAN CHORIONIC GONADOTROPHIN STUDY GROUP: Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment-recombinant HCG versus urinary HCG. Hum. Reprod. (2000) 15:1446-1451.
44. HUGUES JN: Comparative use of urinary and recombinant human chorionic gonadotropins in women. Treat. Endocrinol. (2004) 3:371-379.
45. BELAISCH-ALLART J, DE MOUZON J, LAPOUSTERLE C, MAYER M: The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF program. Hum. Reprod. (1990) 5:163-166.
46. MOCHTAR MH, HOGERZEIL HV, MOL BW: Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial. Hum. Reprod. (1996) 11:1602-1605.
47. PRITTS EA, ATWOOD AK: Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum. Reprod. (2002) 17:2287-2299. An excellent review on luteal supplemantation treatments.
48. TAVANIOTOU A, SMITZ J, BOURGAIN C, DEVROEY P: Comparison between different routes of progesterone administration as luteal phase support in infertility treatment. Hum. Reprod. Update (2000) 6:139-148.
49. SMITZ J, DEVROEY P, FAGUER B, BOURGAIN C, CAMUS M, VAN STEIRTEGHEM AC: A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum. Reprod. (1992) 7:168-175.
50. SMITZ J, BOURGAIN C, VAN WAESBERGHE L, CAMUS M, DEVROEY P, VAN STEIRTEGHEM AC: A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum. Reprod. (1993) 8:40-45.
51. LEWIN A, BENSHUSHAN A, MEZKER E, YANAI N, SCHENKER JG, GOSHEN R: The role of estrogen support during the luteal phase of in vitro fertilization-embryo transfer transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertil. Steril. (1994) 62:121-125.
52. FARHI J, WEISSMAN A, STEINFELD Z, SHORER M, NAHUM H, LEVRAN D: Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil. Steril. (2000) 73:761-766.
53. DEVROEY P, FAUSER BC, PLATTEAU P, BECKERS NG, DHONT M, MANNAERTS BM: Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin-α) for controlled ovarian stimulation before in vitro fertilization. J. Clin. Endocrinol. Metab. (2004) 89:2062-2070.
54. KLEIN J, LOBEL L, POLLAK S et al.: Development and characterization of a long-acting recombinant hFSH agonist. Hum. Reprod. (2003) 18:50-56.
55. MITWALLY MF, CASPER RF: Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr. Opin. Obstet. Gynecol. (2002) 14:255-263.
56. ORVIETO R: Can we eliminate severe ovarian hyperstimulation syndrome. Hum. Reprod. (2005) 20(2):320-322. A very interesting article on severe OHSS and its prevention.
57. MCKENNA SD, PIETROPAOLO M, TOS EG et al.: Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in FSH-primed rats. Endocrinology (2005) 146(1):208-214.
58. MILLAR RP, ZHU YF, CHEN C, STRUTHERS RS: Progress towards the development of non-peptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: therapy implications. Br. Med. Bull. (2000) 56:761-772.
59. BOULOUX PM, HANDELSMAN DJ, JOCKENHOVEL F et al.: FSH-CTP STUDY GROUP: First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum. Reprod. (2001) 16:1592-1597.
60. GUO T, DONG G, FITZPATRICK D et al.: Webb ML discovery of potent biaryl diketopiperazine FSH receptor agonists: rapid lead optimization through parallel synthesis. 228th ACS Meeting. Philadelphia, USA (2004).
61. GOUTOPOULOS A, REDDY A, LIAO Y et al.: Proline and pipecolic acid-based agonists of the follicle-stimulating hormone receptor. 226th ACS Meeting. New York, USA (2003).
62. Arena: UBS Global Life Sciences Conference 2003. Arena Pharmaceuticals, Inc. Company Presentation (2003).
63. JETTER J, KAO W, ROGERS J et al.: Synthesis and in vitro biology of novel 5-alkylated thiazolidinones as FSH agonists. 226th ACS Meeting. New York (2003).
64. KOCHENDOERFER G: Glycopegylated FSH. 3rd International Conference (Part I) in Protein & Peptide Drug Delivery. Philadelphia, PA, USA (2003).
65. Inhale product development update. IDdb Meeting. London, UK (1997).
66. Serono SA. Annual report 2003. Serono SA (2004).
67. NORMAN P: Org-43553. 12th RSC-SCI Symposium (Part III) Medicinal Chemistry. Cambridge, UK (2003).
68. VAN STRATEN NC, SCHOONUS-GERRITSMA GG, VAN SOMEREN R: The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction. Draaijer Chembiochem. (2002).
69. ARMER RE, SMELT KH: Non-peptidic GnRH receptor antagonists. Curr. Med. Chem. (2004) 11:3017-3028. An up to date systematic review of non-peptide oral GnRH-receptor antagonist.
70. SASAKI S, CHO N, NARA Y et al.: Discovery of a thieno[2,3-D]pyrimidine-2, 4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: A highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. J. Med. Chem. (2003) 46:113-124.
71. ZHU YF, GUO Z, GROSS TD, GAO Y et al.: Design and structure-activity relationships of 2-alkyl-3-aminomethyl-6-(3-methoxyphenyl)-7-methyl-8-(2- fluorobenzyl)imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. J. Med. Chem. (2003) 46:1769-1772.
72. TUCCI FC, ZHU YF, GUO Z et al.: 3-(2-aminoalkyl)-1-(2,6-difluorobenzyl)- 5-(2-fluoro-3-methoxyphenyl)-6-methyl-uracils as orally bioavailable antagonists of the human gonadotropin releasing hormone receptor. J. Med. Chem. (2004) 47:3483-3486.
73. JIANG J, DEVITA JR, GOULET MT et al.: Syntheses and structure-activity relationships studies of Piperidine-substituted quiniolones as non-peptide gonadotropin releasing hormone antagonists. National Medicinal Chemistry Symposium. (2002).
74. METCALF D:. The unsolved enigmas of leukemia inhibitory factor. Stem Cells (2003) 21:5-14. This review illustrates the potential implications of LIF in infertility.
75. BRINSDEN PR, NDUKWE G, ENGRAND P et al.: Does recombinant human leukaemia inhibitory factor improve implantation in women with recurrent failure of assisted reproduction treatment? Hum. Reprod. (2003) 18:18.
76. TREADWAY DR, BURAGLIO M, HEMSEY G, DENTON G: A Phase I study of the pharmacodynamic and safety of single - and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil. Steril. (2004) 82:1587-1593.
77. MITWALLY MF, CASPER RF: Aromatase inhibition reduces gonadotropin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum. Reprod. (2003) 18:1588-1597.
78. FATEMI HM, KOLIBIANAKIS E, TOURNAYE H, CAMUS M, VAN STEIRTEGHEM AC, DEVROEY P: Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod. Biomed. Online (2003) 7:543-546.
79. GRONDAHL C, BREINHOLT J, WAHL P et al.: Physiology of meiosis-activating sterol: endogenous formation and mode of action. Hum. Reprod. (2003) 18:122-129.
80. BERGH C, LOFT A, LUNDIN K et al.: CEMAS II Study Group: Chromosomal abnormality rate in human pre-embryos derived from in vitro fertilization cycles cultured in the presence of follicular-fluid meiosis activating sterol (FF-MAS). Hum. Reprod. (2004) 1:2109-2117.
81. PALMER S, CAMPEN CA, ALLAN GF et al.: Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity. J. Steroid Biochem. Mol. Biol. (2000) 75:33-42.
82. 2 receptors agonists. 228th ACS Meeting. Philadelphia (2004).
83. WELT CK, CHAN JL, BULLEN J et al.: Recombinant human leptin in women with hypothalamic amenorrhea. N. Engl. J. Med. (2004) 351:987-997. An impressive study about the role of recombinant human leptin.
84. HAYES ES: Biology of primate relaxin: a paracrine signal in early pregnancy. Reprod. Biol. Endocrinol. (2004) 16:36.